Related Experiment Video
Updated: Apr 11, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions
A K Das1, S Dhanure1, A K Savalia1
1Clinical Research and Pharmacovigilance, Micro Labs Limited, Bangalore-560 068, India.
Abstract:
The bioequivalence of two different tablet formulations containing losartan potassium 100 mg was determined in healthy volunteers after a single oral dose in a randomized crossover study. Test and reference products were administered to 60 volunteers with 240 ml water after overnight fasting. Plasma concentrations of losartan and its active carboxylic acid metabolite were monitored over a period of 36 h after drug administration by validated LC/MS/MS analytical method. The pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞, AUC0-t/AUC0-∞, tmax, Kel and t½ were determined from plasma concentration time profile of both formulations for losartan and its active metabolite losartan carboxylic acid and were found to be in good agreement. The carboxylic acid metabolite was considered for profiling purpose only. The analysis of variance did not show any significant difference between the two formulations and 90% confidence intervals for the ratio of Cmax (84.89-104.09%), AUC0-t (95.84-102.84%) and AUC0-∞ (96.43-103.25%) values for losartan between the test and reference products were within the 80-125% interval, satisfying the bioequivalence criteria of the US FDA guidelines. These results indicate that the test and the reference products of losartan potassium are bioequivalent and, thus, may be prescribed interchangeably.
Related Concept Videos
Bioequivalence studies: Biowaivers
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence: Overview
Bioequivalence Data: Statistical Interpretation
Bioequivalence of Drugs: Drugs with Multiple Indications
Dose-Response Relationship: Potency and Efficacy

